Literature DB >> 34458740

Design, synthesis and biological evaluation of combretastatin A-4 sulfamate derivatives as potential anti-cancer agents.

Leilei Huang1, Jinwen Huang1,2,3, Hui Nie1, Yingzi Li1, Lixing Song1, Fanhong Wu1,2.   

Abstract

A series of combretastatin A-4 (CA-4) sulfamate derivatives were synthesized and their structure-activity relationship on tubulin, arylsulfatase and tumor cell antiproliferation inhibition was studied. Among them, compound 16a showed excellent potency as well as CA-4 under the same conditions against six tumor cells including HTC-116, HeLa, HepG2, MGC803, MKN45 and MCF-7 cells, respectively. Molecular docking revealed that several important hydrogen bond interactions were formed between the sulfamate group of 16a and the colchicine binding site of tubulin and steroid sulfatase respectively. Although compound 16a was less active than CA-4 in regard to its in vitro activity as an inhibitor of tubulin polymerization, it was effective as an inhibitor of arylsulfatase. This novel combretastatin A-4 sulfamate derivative has the potential to be developed as a dual inhibitor of tubulin polymerization and arylsulfatase for cancer therapy. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34458740      PMCID: PMC8372205          DOI: 10.1039/d0md00372g

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  43 in total

1.  Drug development: Raise standards for preclinical cancer research.

Authors:  C Glenn Begley; Lee M Ellis
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

Review 2.  Novel agents that target tublin and related elements.

Authors:  Eric K Rowinsky; Emiliano Calvo
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

Review 3.  Tubulins as therapeutic targets in cancer: from bench to bedside.

Authors:  Christos D Katsetos; Pavel Dráber
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.

Authors:  Rastislav Bahleda; Cristiana Sessa; Gianluca Del Conte; Luca Gianni; Giuseppe Capri; Andrea Varga; Corina Oprea; Byzance Daglish; Marie Hospitel; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2014-06-06       Impact factor: 3.850

Review 6.  Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option.

Authors:  Richard R Love
Journal:  Clin Breast Cancer       Date:  2016-03-31       Impact factor: 3.225

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Authors:  F A L M Eskens; P Tresca; D Tosi; L Van Doorn; H Fontaine; A Van der Gaast; C Veyrat-Follet; C Oprea; M Hospitel; V Dieras
Journal:  Br J Cancer       Date:  2014-04-08       Impact factor: 7.640

9.  The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate.

Authors:  Toby Holmes; Andrew W Brown; Marie Suggitt; Lucy A Shaw; Lucy Simpson; Joseph P A Harrity; Gillian M Tozer; Chryso Kanthou
Journal:  Sci Rep       Date:  2020-06-18       Impact factor: 4.379

10.  A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Authors:  Edward B Garon; Jeffrey D Neidhart; Nashat Y Gabrail; Moacyr R de Oliveira; Jai Balkissoon; Fairooz Kabbinavar
Journal:  Onco Targets Ther       Date:  2016-11-30       Impact factor: 4.147

View more
  1 in total

Review 1.  Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function.

Authors:  Lijiang Huang; Yan Peng; Xuetao Tao; Xiaoxiao Ding; Rui Li; Yongsheng Jiang; Wei Zuo
Journal:  Oxid Med Cell Longev       Date:  2022-03-07       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.